甲状腺功能低下症中的肠道微生物群:致病机制和精确微生物群干预的机会
Tao Jiang1, Xiuqing Yang2, Baihui Wu2
1Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou, China.
Frontiers in microbiology
|October 17, 2025
概括
肠道微生物群影响甲状腺功能低下,影响甲状腺功能和患者的症状. 针对微生物群的治疗有望改善这种常见的内分泌疾病的管理和结果.
科学领域:
- 内分泌学和新陈代谢学
- 微生物组研究 微生物组研究
- 免疫学 免疫学 免疫学
背景情况:
- 甲状腺功能低下症,通常是由于哈西莫托的甲状腺炎,在一些患者中,尽管接受了levothyroxine治疗,但仍然存在.
- 肠道失生症越来越多地通过免疫和炎症途径与甲状腺功能低下症的发病有关.
- 微生物代谢物和肠-甲状腺轴是研究的新兴领域.
研究的目的:
- 探索肠道微生物群和甲状腺功能低下之间的机制联系.
- 评估当前基于微生物群的治疗策略.
- 突出微生物驱动型甲状腺功能低下症管理的未来方向.
主要方法:
- 对现有文献进行系统审查.
- 对肠道微生物群的组成和功能在甲状腺功能低下的研究的分析.
- 对针对微生物群的干预措施的临床试验数据的评估.
主要成果:
- 肠道失调有助于通过免疫失调,增加肠道透性和炎症导致甲状腺功能低下.
- 微生物代谢物影响甲状腺激素代谢和组织敏感性.
- 针对微生物群的干预措施显示出改善甲状腺功能和减少症状的潜力.
结论:
- 肠-甲状腺轴为甲状腺功能低下症提供了一个新的视角.
- 微生物群调制为新的治疗策略提供了一个有希望的途径.
- 个性化,微生物驱动的干预措施可以优化甲状腺功能低下症的管理.
相关概念视频
Microorganisms in Medicine and Therapeutics
936
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
936
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
635
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
635
Irritable Bowel Syndrome I: Introduction
916
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
916
Fungal Phylum Microsporidia
417
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
417
What is Monogastric Digestion?
74.9K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
74.9K
Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496


